Antibodies against somatostatin receptor 2A (SSTR2A), TP53, RB, cyclin dependent kinase inhibitor 2A (CDKN2A [P16]), and BCL2 apoptosis regulator (BCL2) are commonly used to assess the genetic status of sporadic pancreatic NETs and NECs, with a higher prevalence of TP53 mutations and RB protein inactivation in NECs (7–9). Here, BCL2 is linked to pancreatic neuroendocrine tumor.